PAC-1 is under clinical development by Vanquish Oncology and currently in Phase I for Pancreatic Endocrine Tumor. According to GlobalData, Phase I drugs for Pancreatic Endocrine Tumor have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PAC-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PAC-1 (also known as VO-100) is under development for the treatment of anaplastic astrocytoma, glioblastoma multiforme (gbm), metastatic uveal melanoma, neuroendocrine tumors, lymphoma, pancreatic neuroendocrine tumor and solid tumors. The drug candidate is formulated as a capsule and administered orally and it acts by targeting a cellular enzyme, procaspase-3.
Vanquish Oncology overview
Vanquish Oncology is a biotechnology company which develops targeted, small-molecule oncology therapeutics for unmet or underserved cancer markets. The company is headquartered in Champaign, Illinois, the US.
For a complete picture of PAC-1’s drug-specific PTSR and LoA scores, buy the report here.